Sanofi India Limited

SANOFI
LTP N/A
Latest Quarter Update

Strong Growth in Diabetes Segment Strategic initiatives drive performance

Diabetes Segment Revenue Growth

10% YoY growth

₹Y billion

Launch of Soliqua exceeding initial expectations

Partnerships with Emcure and Cipla enhancing distribution

Explore Future Opportunities

Earning Calls History

Q2 FY2024 - May 16, 2024
Latest
Stable performance with strategic advancements.
Sanofi India reported a stable performance in Q1 2024, driven by strategic initiatives across its diabetes and consumer healthcare segments. The successful launch of Soliqua marks a significant advancement in their product offerings, positioning the company for future growth.
Dig Deeper